Dr. Iris Ziegler

Dr. Iris M. Ziegler obtained her PhD in 1996 from the Ludwig-Maximilians-Universität in Munich. After her post-doctoral studies at SmithKline Beecham Pharmaceuticals in Great Burgh, Great Britain she held different positions in Pharmaceutical Development and as International Project Manager at Grünenthal and as Director of Pharmaceutical Development at Nycomed.

In 2012 she joined Corden Pharma Plankstadt as Director Development and Production and Board Member responsible for Business Development, Project Management, Development and Production.

Since 2017 Iris Ziegler has been responsible for the introduction of new technologies and QbD in all sites of the Corden Pharma Group as Director of Pharmaceutical Sciences and QbD at Corden Pharma International.

A QbD driven development approach based on the systematic, risk-based and science driven design and development of pharmaceutical products has always been a key focus in her work.

Iris M. Ziegler is an expert on pelletisation, extrusion, coating, sustained release dosage forms, solid dosage form manufacturing, the containment of highly potent compounds, and a QbD driven development. She has authored and co-authored several papers and given many lectures, seminars, and presentations on these topics.

She has published and co-authored several papers and a chapter for the 2nd edition of Michael J. Rathbone’s Modified Release Drug Delivery Technology on “Dose Sipping Technology—A Novel Dosage Form for the Administration of Drugs”, a novel drug delivery technology, she was strongly involved in while working at Grünenthal.

She is the inventor and co-inventor of several patent applications and holds several patents in the area of oral sustained release formulations and oral drug delivery systems.

Since 2006 she has been a member of the APV’s Focus Group “Solid Dosage Forms” and was the Focus Group leader from 2017 to 2022.